Replacing Phosphorus-Containing Food Additives With Foods Without Additives Reduces Phosphatemia in End-Stage Renal Disease Patients: A Randomized Clinical Trial

被引:39
|
作者
Leite de Fornasari, Margareth Lage [1 ]
dos Santos Sens, Yvoty Alves [2 ]
机构
[1] Sch Med Sci, Post Graduat Hlth Sci, Div Santa Casa Sao Paulo, Sao Paulo, Brazil
[2] Nephron Grp, Substitut Renal Therapy, Sao Paulo, SP, Brazil
关键词
CHRONIC KIDNEY-DISEASE; DIETARY-PROTEIN INTAKE; HEMODIALYSIS-PATIENTS; HEALTH IMPACT; HYPERPHOSPHATEMIA; MORTALITY; METABOLISM; GUIDELINES; MANAGEMENT; SURVIVAL;
D O I
10.1053/j.jrn.2016.08.009
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Objective: The purpose of the study was to verify the effects of replacing phosphorus-containing food additives with foods without additives on phosphatemia in end-stage renal disease (ESRD) patients. Design: Randomized clinical trial. Setting: Adult patients on hemodialysis for >= 6 months at a single center. Subjects: A total of 134 patients with phosphorus levels of. 5.5 mg/dL were included and were randomized into an intervention group (n 5 67) and a control group (n 5 67). Intervention: The IG received individual orientation to replace processed foods that have phosphorus additives with foods of similar nutritional value without these additives. The CG received only the nutritional orientation given before the study. Clinical laboratory data, nutritional status, energy and protein intake, and normalized protein nitrogen appearance (nPNA) were evaluated at the beginning of the study and after 90 days. Results: There was no initial difference between the groups in terms of serum phosphorus levels, nutritional status, and energy intake. After 3 months, there was a decline in phosphorus levels in the IG (from 7.2 +/- 1.4 to 5.0 +/- 1.3 mg/dL, P < .001), but there was no significant difference in the CG (from 7.1 +/- 1.2 to 6.7 +/- 1.2 mg/dL, P =.65). In the IG, 69.7% of the patients reached the serum phosphorus target of <= 5.5 mg/dL; however, only 18.5% of the CG subjects reached this level (P,.001). Conclusion: At the end, there was no difference between the two groups in terms of nutritional status, energy intake, protein intake, and nPNA. The replacing phosphorus-containing food additives with foods without additives reduced serum phosphorus without interfering in the nutritional status of ESRD patients. (C) 2016 by the National Kidney Foundation, Inc. All rights reserved.
引用
收藏
页码:97 / 105
页数:9
相关论文
共 50 条
  • [31] Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial
    Pakfetrat, Maryam
    Basiri, Fatemeh
    Malekmakan, Leila
    Roozbeh, Jamshid
    JOURNAL OF NEPHROLOGY, 2014, 27 (02) : 203 - 207
  • [32] Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial
    Maryam Pakfetrat
    Fatemeh Basiri
    Leila Malekmakan
    Jamshid Roozbeh
    Journal of Nephrology, 2014, 27 : 203 - 207
  • [33] Home-Based Group Education On Renal Replacement Therapy For Patients With End-Stage Renal Disease: A Multi-Center Randomized Controlled Trial
    Massey, E.
    Gregoor, P. Smak
    Nette, R.
    van den Dorpel, M.
    van Kooij, A.
    Betjes, M.
    Zietse, R.
    Zuidema, W.
    Timman, R.
    Busschbach, J.
    Weimar, W.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 488 - 488
  • [34] The Effectiveness of Vitamin D Supplementation on Oxidative and Inflammatory Markers in Patients Suffering from End-stage Renal Disease, a Randomized Controlled Trial
    Sharif, Dana Ahmed
    CELLULAR AND MOLECULAR BIOLOGY, 2022, 68 (05) : 7 - 15
  • [35] Home-Based Group Education On Renal Replacement Therapy For Patients With End-Stage Renal Disease: A Multi-Center Randomized Controlled Trial.
    Massey, E.
    Gregoor, P. Smak
    Nette, R.
    van den Dorpel, M.
    van Kooij, A.
    Betjes, M.
    Zietse, R.
    Zuidema, W.
    Timman, R.
    Busschbach, J.
    Weimar, W.
    TRANSPLANTATION, 2014, 98 : 488 - 488
  • [36] Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial
    Verbout, Norah G.
    Lorentz, Christina U.
    Markway, Brandon D.
    Wallisch, Michael
    Marbury, Thomas C.
    Di Cera, Enrico
    Shatzel, Joseph J.
    Gruber, Andras
    Tucker, Erik I.
    COMMUNICATIONS MEDICINE, 2024, 4 (01):
  • [37] Sustained-release diltiazem reduces myocardial ischemic episodes in end-stage renal disease:: A double-blind, randomized, crossover, placebo-controlled trial
    Cice, G
    Di Benedetto, A
    D'Andrea, A
    D'Isa, S
    Ferrara, L
    Russo, PE
    Iacono, A
    Calabrò, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (04): : 1006 - 1011
  • [38] An Acetate-Buffered Balanced Crystalloid Versus 0.9% Saline in Patients with End-Stage Renal Disease Undergoing Cadaveric Renal Transplantation: A Prospective Randomized Controlled Trial
    Potura, Eva
    Lindner, Gregor
    Biesenbach, Peter
    Funk, Georg-Christian
    Reiterer, Christian
    Kabon, Barbara
    Schwarz, Christoph
    Druml, Wilfred
    Fleischmann, Edith
    ANESTHESIA AND ANALGESIA, 2015, 120 (01): : 123 - 129
  • [39] The Impact of Intradialytic Cognitive and Physical Training Program on the Physical and Cognitive Abilities in End-Stage Kidney Disease Patients: A Randomized Clinical Controlled Trial
    Kren, Aljaz
    Bogataj, Spela
    BRAIN SCIENCES, 2023, 13 (08)
  • [40] RECOMBINANT HUMAN ERYTHROPOIETIN IN ANEMIC PATIENTS WITH END-STAGE RENAL-DISEASE - RESULTS OF A PHASE-III MULTICENTER CLINICAL-TRIAL
    ESCHBACH, JW
    ABDULHADI, MH
    BROWNE, JK
    DELANO, BG
    DOWNING, MR
    EGRIE, JC
    EVANS, RW
    FRIEDMAN, EA
    GRABER, SE
    HALEY, NR
    KORBET, S
    KRANTZ, SB
    LUNDIN, AP
    NISSENSON, AR
    OGDEN, DA
    PAGANINI, EP
    RADER, B
    RUTSKY, EA
    STIVELMAN, J
    STONE, WJ
    TESCHAN, P
    VANSTONE, JC
    VANWYCK, DB
    ZUCKERMAN, K
    ADAMSON, JW
    ANNALS OF INTERNAL MEDICINE, 1989, 111 (12) : 992 - 1000